{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:16:15Z","timestamp":1790630175552,"version":"4.1.0"},"reference-count":146,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T00:00:00Z","timestamp":1630972800000},"content-version":"am","delay-in-days":371,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-10-IAHU-01 ANR-18-RHUS-00101"],"award-info":[{"award-number":["ANR-10-IAHU-01 ANR-18-RHUS-00101"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","award":["2014-1-PL BIO-10"],"award-info":[{"award-number":["2014-1-PL BIO-10"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002915","name":"Fondation pour la Recherche M\u00e9dicale","doi-asserted-by":"publisher","award":["SPF20170938825"],"award-info":[{"award-number":["SPF20170938825"]}],"id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.blre.2020.100652","type":"journal-article","created":{"date-parts":[[2020,1,16]],"date-time":"2020-01-16T02:05:34Z","timestamp":1579140334000},"page":"100652","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["After 95\u202fyears, it's time to eRASe JMML"],"prefix":"10.1016","volume":"43","author":[{"given":"Sonia","family":"Meynier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Rieux-Laucat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.blre.2020.100652_bb0005","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood.V96.6.2310","article-title":"Evidence that juvenile myelomonocytic leukemia can arise from a pluripotential stem cell","volume":"96","author":"Cooper","year":"2000","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.blre.2020.100652_bb0010","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.1182\/blood.V88.11.4314.bloodjournal88114314","article-title":"Patterns of hematopoietic lineage involvement in children with neurofibromatosis type 1 and malignant myeloid disorders","volume":"88","author":"Miles","year":"1996","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2020.100652_bb0015","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0145-2126(02)00178-9","article-title":"B lineage acute lymphoblastic leukemia transformation in a child with juvenile myelomonocytic leukemia, type 1 neurofibromatosis and monosomy of chromosome 7. Possible implications in the leukemogenesis","volume":"27","author":"Scrideli","year":"2003","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2020.100652_bb0020","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/BF02224929","volume":"38","year":"1924","journal-title":"Z Kinderh"},{"issue":"10","key":"10.1016\/j.blre.2020.100652_bb0025","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1182\/blood-2018-11-844688","article-title":"Juvenile myelomonocytic leukemia: who's the driver at the wheel?","volume":"33","author":"Niemeyer","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2020.100652_bb0030","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.leukres.2008.08.022","article-title":"Juvenile myelomonocytic leukemia: a report from the 2nd International JMML Symposium","volume":"33","author":"Chan","year":"2009","journal-title":"Leuk Res"},{"issue":"10","key":"10.1016\/j.blre.2020.100652_bb0035","first-page":"3534","article-title":"Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS)","volume":"89","author":"Niemeyer","year":"1997","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2020.100652_bb0040","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/blood-2004-05-1944","article-title":"Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS\/EBMT trial","volume":"105","author":"Locatelli","year":"2005","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2020.100652_bb0045","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s12185-014-1715-7","article-title":"Transplantation for juvenile myelomonocytic leukemia: a retrospective study of 30 children treated with a regimen of busulfan, fludarabine, and melphalan","volume":"101","author":"Yabe","year":"2015","journal-title":"Int J Hematol"},{"issue":"12","key":"10.1016\/j.blre.2020.100652_bb0050","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1182\/blood-2013-03-491589","article-title":"Analysis of risk factors influencing outcomes after cord blood transplantation in children with juvenile myelomonocytic leukemia: a EUROCORD, EBMT, EWOG-MDS, CIBMTR study","volume":"122","author":"Locatelli","year":"2013","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2020.100652_bb0055","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1182\/blood-2010-07-295501","article-title":"Somatic KRAS mutations associated with a human nonmalignant syndrome of autoimmunity and abnormal leukocyte homeostasis","volume":"117","author":"Niemela","year":"2011","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2020.100652_bb0060","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1038\/leu.2013.82","article-title":"Autoimmunity and persistent RAS-mutated clones long after the spontaneous regression of JMML","volume":"27","author":"Takagi","year":"2013","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.blre.2020.100652_bb0065","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/bjh.12796","article-title":"Clinical characteristics of 15 children with juvenile myelomonocytic leukaemia who developed blast crisis: MDS Committee of Japanese Society of Paediatric Haematology\/Oncology","volume":"165","author":"Honda","year":"2014","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.blre.2020.100652_bb0070","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/1097-0142(1984)54:4<675::AID-CNCR2820540415>3.0.CO;2-Q","article-title":"Subacute and chronic myelomonocytic leukemia in children (juvenile CML). Clinical and hematologic observations, and identification of prognostic factors","volume":"54","author":"Castro-Malaspina","year":"1984","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.blre.2020.100652_bb0075","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.1182\/blood-2006-09-046649","article-title":"Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations","volume":"109","author":"Matsuda","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2020.100652_bb0080","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/00043426-199703000-00019","article-title":"Spontaneous remission of juvenile chronic myelomonocytic leukemia in an infant with Noonan syndrome","volume":"19","author":"Fukuda","year":"1997","journal-title":"J Pediatr Hematol Oncol"},{"issue":"7","key":"10.1016\/j.blre.2020.100652_bb0085","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26408","article-title":"Transient juvenile myelomonocytic leukemia in the setting of PTPN11 mutation and Noonan syndrome with secondary development of monosomy 7","volume":"64","author":"O'Halloran","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.blre.2020.100652_bb0090","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","volume":"Vol. 2","author":"Swerdlow","year":"2017"},{"issue":"8","key":"10.1016\/j.blre.2020.100652_bb0095","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/ped.13068","article-title":"Diagnosis and treatment of juvenile myelomonocytic leukemia","volume":"58","author":"Sakashita","year":"2016","journal-title":"Pediatr Int"},{"issue":"7","key":"10.1016\/j.blre.2020.100652_bb0100","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1182\/blood-2014-08-550483","article-title":"How I treat juvenile myelomonocytic leukemia","volume":"125","author":"Locatelli","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2020.100652_bb0105","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1182\/blood.V90.2.479","article-title":"Juvenile myelomonocytic leukemia","volume":"90","author":"Arico","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100652_bb0110","series-title":"Cancer in children: Clinical management","author":"Michael","year":"2012"},{"issue":"2","key":"10.1016\/j.blre.2020.100652_bb0115","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3324\/haematol.2009.016865","article-title":"Molecular basis of juvenile myelomonocytic leukemia","volume":"95","author":"de Vries","year":"2010","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.blre.2020.100652_bb0120","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4274\/tjh.2017.0021","article-title":"Juvenile myelomonocytic leukemia in Turkey: a retrospective analysis of sixty-five patients","volume":"35","author":"Tufekci","year":"2018","journal-title":"Turk J Haematol"},{"issue":"11","key":"10.1016\/j.blre.2020.100652_bb0125","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1038\/ng.3400","article-title":"The genomic landscape of juvenile myelomonocytic leukemia","volume":"47","author":"Stieglitz","year":"2015","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.blre.2020.100652_bb0130","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/sj.leu.2401240","article-title":"RAS mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML)","volume":"13","author":"Flotho","year":"1999","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.blre.2020.100652_bb0135","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/j.1365-2141.2009.07894.x","article-title":"Germ-line mutation of the NRAS gene may be responsible for the development of juvenile myelomonocytic leukaemia","volume":"147","author":"De Filippi","year":"2009","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.blre.2020.100652_bb0140","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1002\/ajmg.a.35513","article-title":"Constitutional NRAS mutations are rare among patients with Noonan syndrome or juvenile myelomonocytic leukemia","volume":"158A","author":"Kraoua","year":"2012","journal-title":"Am J Med Genet A"},{"issue":"7","key":"10.1016\/j.blre.2020.100652_bb0145","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1182\/blood-2012-02-406090","article-title":"Somatic mosaicism for oncogenic NRAS mutations in juvenile myelomonocytic leukemia","volume":"120","author":"Doisaki","year":"2012","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.blre.2020.100652_bb0150","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/ng.3420","article-title":"Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network","volume":"47","author":"Caye","year":"2015","journal-title":"Nat Genet"},{"issue":"6","key":"10.1016\/j.blre.2020.100652_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2013.01.003","article-title":"Aggressive transformation of juvenile myelomonocytic leukemia associated with duplication of oncogenic KRAS due to acquired uniparental disomy","volume":"162","author":"Kato","year":"2013","journal-title":"J Pediatr"},{"issue":"6","key":"10.1016\/j.blre.2020.100652_bb0160","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1182\/blood-2008-01-134262","article-title":"Oncogenic Kras-induced leukemogeneis: hematopoietic stem cells as the initial target and lineage-specific progenitors as the potential targets for final leukemic transformation","volume":"113","author":"Zhang","year":"2009","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.blre.2020.100652_bb0165","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.3324\/haematol.11503","article-title":"Acquisition of loss of the wild-type NRAS locus with aggressive disease progression in a patient with juvenile myelomonocytic leukemia and a heterozygous NRAS mutation","volume":"92","author":"Matsuda","year":"2007","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.blre.2020.100652_bb0170","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1182\/blood-2010-08-301515","article-title":"Autoimmune lymphoproliferative syndrome-like disease with somatic KRAS mutation","volume":"117","author":"Takagi","year":"2011","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.blre.2020.100652_bb0175","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/ced.13668","article-title":"Cutaneous involvement in an 8-year-old boy with Ras-associated autoimmune leucoproliferative disorder (RALD)","volume":"43","author":"Giacaman","year":"2018","journal-title":"Clin Exp Dermatol"},{"issue":"18","key":"10.1016\/j.blre.2020.100652_bb0180","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood-2014-11-567917","article-title":"JMML and RALD (Ras-associated autoimmune leukoproliferative disorder): common genetic etiology yet clinically distinct entities","volume":"125","author":"Calvo","year":"2015","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.blre.2020.100652_bb0185","first-page":"853","article-title":"Ras-associated autoimmune leukoproliferative disorder: a report of 2 cases and literature review","volume":"55","author":"He","year":"2017","journal-title":"Zhonghua Er Ke Za Zhi"},{"issue":"21","key":"10.1016\/j.blre.2020.100652_bb0190","doi-asserted-by":"crossref","first-page":"8953","DOI":"10.1073\/pnas.0702975104","article-title":"NRAS mutation causes a human autoimmune lymphoproliferative syndrome","volume":"104","author":"Oliveira","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"10.1016\/j.blre.2020.100652_bb0195","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1182\/blood-2014-01-548958","article-title":"RAS-associated lymphoproliferative disease evolves into severe juvenile myelo-monocytic leukemia","volume":"123","author":"Lanzarotti","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2020.100652_bb0200","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/cei.12986","article-title":"T and B cell clonal expansion in Ras-associated lymphoproliferative disease (RALD) as revealed by next-generation sequencing","volume":"189","author":"Levy-Mendelovich","year":"2017","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"10.1016\/j.blre.2020.100652_bb0205","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1007\/s10875-015-0163-3","article-title":"Somatic mosaicism for a NRAS mutation associates with disparate clinical features in RAS-associated leukoproliferative disease: a report of two cases","volume":"35","author":"Shiota","year":"2015","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.blre.2020.100652_bb0210","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.clim.2016.12.006","article-title":"The importance of considering monogenic causes of autoimmunity: a somatic mutation in KRAS causing pediatric Rosai-Dorfman syndrome and systemic lupus erythematosus","volume":"175","author":"Ragotte","year":"2017","journal-title":"Clin Immunol"},{"issue":"4","key":"10.1016\/j.blre.2020.100652_bb0215","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/humu.23399","article-title":"Somatic mutations activating Wiskott\u2013Aldrich syndrome protein concomitant with RAS pathway mutations in juvenile myelomonocytic leukemia patients","volume":"39","author":"Coppe","year":"2018","journal-title":"Hum Mutat"},{"issue":"9","key":"10.1016\/j.blre.2020.100652_bb0220","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1038\/leu.2015.85","article-title":"Loss of Dnmt3a and endogenous Kras(G12D\/+) cooperate to regulate hematopoietic stem and progenitor cell functions in leukemogenesis","volume":"29","author":"Chang","year":"2015","journal-title":"Leukemia"},{"issue":"14","key":"10.1016\/j.blre.2020.100652_bb0225","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1182\/blood-2017-07-798157","article-title":"Integrated molecular profiling of juvenile myelomonocytic leukemia","volume":"131","author":"Murakami","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2020.100652_bb0230","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-02178-9","article-title":"Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia","volume":"8","author":"Stieglitz","year":"2017","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.blre.2020.100652_bb0235","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-02177-w","article-title":"RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia","volume":"8","author":"Lipka","year":"2017","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.blre.2020.100652_bb0240","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0968-0004(03)00091-4","article-title":"The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling","volume":"28","author":"Neel","year":"2003","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.blre.2020.100652_bb0245","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms9859","article-title":"Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis","volume":"6","author":"Bunda","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2020.100652_bb0250","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.semcdb.2016.06.006","article-title":"New structural and functional insight into the regulation of Ras","volume":"58","author":"Kano","year":"2016","journal-title":"Semin Cell Dev Biol"},{"issue":"6","key":"10.1016\/j.blre.2020.100652_bb0255","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/00043426-199911000-00014","article-title":"Juvenile myelomonocytic leukemia and Noonan syndrome","volume":"21","author":"Choong","year":"1999","journal-title":"J Pediatr Hematol Oncol"},{"issue":"11","key":"10.1016\/j.blre.2020.100652_bb0260","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.3324\/haematol.2014.114595","article-title":"RAS diseases in children","volume":"99","author":"Niemeyer","year":"2014","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.blre.2020.100652_bb0265","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/jmedgenet-2014-102611","article-title":"Juvenile myelomonocytic leukaemia and Noonan syndrome","volume":"51","author":"Strullu","year":"2014","journal-title":"J Med Genet"},{"issue":"6","key":"10.1016\/j.blre.2020.100652_bb0270","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1182\/blood-2005-02-0531","article-title":"The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome\/myeloproliferative disease","volume":"106","author":"Kratz","year":"2005","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2020.100652_bb0275","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/ng1156","article-title":"Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia","volume":"34","author":"Tartaglia","year":"2003","journal-title":"Nat Genet"},{"issue":"6","key":"10.1016\/j.blre.2020.100652_bb0280","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2003-09-3287","article-title":"Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis","volume":"103","author":"Loh","year":"2004","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2020.100652_bb0285","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1365-2141.2009.07968.x","article-title":"Quantitative assessment of PTPN11 or RAS mutations at the neonatal period and during the clinical course in patients with juvenile myelomonocytic leukaemia","volume":"148","author":"Matsuda","year":"2010","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.blre.2020.100652_bb0290","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.exphem.2008.04.016","article-title":"Activating PTPN11 mutants promote hematopoietic progenitor cell-cycle progression and survival","volume":"36","author":"Yang","year":"2008","journal-title":"Exp Hematol"},{"issue":"9","key":"10.1016\/j.blre.2020.100652_bb0295","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1182\/blood-2004-10-4002","article-title":"Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor","volume":"105","author":"Chan","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2020.100652_bb0300","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1182\/blood-2004-11-4207","article-title":"Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells","volume":"106","author":"Schubbert","year":"2005","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.blre.2020.100652_bb0305","doi-asserted-by":"crossref","first-page":"4376","DOI":"10.1128\/MCB.01330-08","article-title":"Increased c-Jun expression and reduced GATA2 expression promote aberrant monocytic differentiation induced by activating PTPN11 mutants","volume":"29","author":"Yang","year":"2009","journal-title":"Mol Cell Biol"},{"issue":"2","key":"10.1016\/j.blre.2020.100652_bb0310","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/cdd.2013.145","article-title":"Transcriptional fine-tuning of microRNA-223 levels directs lineage choice of human hematopoietic progenitors","volume":"21","author":"Vian","year":"2014","journal-title":"Cell Death Differ"},{"issue":"9","key":"10.1016\/j.blre.2020.100652_bb0315","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1006259","article-title":"The PU.1-modulated microRNA-22 is a regulator of monocyte\/macrophage differentiation and acute myeloid leukemia","volume":"12","author":"Shen","year":"2016","journal-title":"PLoS Genet"},{"issue":"3","key":"10.1016\/j.blre.2020.100652_bb0320","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.celrep.2015.09.019","article-title":"Myeloid dysregulation in a human induced pluripotent stem cell model of PTPN11-associated juvenile myelomonocytic leukemia","volume":"13","author":"Mulero-Navarro","year":"2015","journal-title":"Cell Rep"},{"issue":"18","key":"10.1016\/j.blre.2020.100652_bb0325","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1182\/blood-2010-01-265652","article-title":"A germline gain-of-function mutation in Ptpn11 (Shp-2) phosphatase induces myeloproliferative disease by aberrant activation of hematopoietic stem cells","volume":"116","author":"Xu","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2020.100652_bb0330","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/leu.2016.326","article-title":"Inhibition of the Gab2\/PI3K\/mTOR signaling ameliorates myeloid malignancy caused by Ptpn11 (Shp2) gain-of-function mutations","volume":"31","author":"Liu","year":"2017","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.blre.2020.100652_bb0335","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1084\/jem.20110450","article-title":"Non-lineage\/stage-restricted effects of a gain-of-function mutation in tyrosine phosphatase Ptpn11 (Shp2) on malignant transformation of hematopoietic cells","volume":"208","author":"Xu","year":"2011","journal-title":"J Exp Med"},{"issue":"3","key":"10.1016\/j.blre.2020.100652_bb0340","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1203\/PDR.0b013e3181961d2a","article-title":"Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia","volume":"65","author":"Yoshida","year":"2009","journal-title":"Pediatr Res"},{"issue":"2","key":"10.1016\/j.blre.2020.100652_bb0345","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ccr.2005.01.010","article-title":"Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations","volume":"7","author":"Mohi","year":"2005","journal-title":"Cancer Cell"},{"issue":"18","key":"10.1016\/j.blre.2020.100652_bb0350","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1182\/blood-2008-10-182626","article-title":"Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis","volume":"113","author":"Chan","year":"2009","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2020.100652_bb0355","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1172\/JCI94031","article-title":"Mice expressing KrasG12D in hematopoietic multipotent progenitor cells develop neonatal myeloid leukemia","volume":"127","author":"Tarnawsky","year":"2017","journal-title":"J Clin Invest"},{"issue":"7628","key":"10.1016\/j.blre.2020.100652_bb0360","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/nature20131","article-title":"Leukaemogenic effects of Ptpn11 activating mutations in the stem cell microenvironment","volume":"539","author":"Dong","year":"2016","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.blre.2020.100652_bb0365","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1080\/15592294.2016.1145327","article-title":"Epigenetic silencing of AKAP12 in juvenile myelomonocytic leukemia","volume":"11","author":"Wilhelm","year":"2016","journal-title":"Epigenetics"},{"issue":"9","key":"10.1016\/j.blre.2020.100652_bb0370","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.4161\/epi.29941","article-title":"RASA4 undergoes DNA hypermethylation in resistant juvenile myelomonocytic leukemia","volume":"9","author":"Poetsch","year":"2014","journal-title":"Epigenetics"},{"issue":"7","key":"10.1016\/j.blre.2020.100652_bb0375","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1038\/leu.2013.49","article-title":"Deficiency of CREB and over expression of miR-183 in juvenile myelomonocytic leukemia","volume":"27","author":"Liu","year":"2013","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.blre.2020.100652_bb0380","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.leukres.2008.09.036","article-title":"PTEN deficiency is a common defect in juvenile myelomonocytic leukemia","volume":"33","author":"Liu","year":"2009","journal-title":"Leuk Res"},{"issue":"21","key":"10.1016\/j.blre.2020.100652_bb0385","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1038\/sj.emboj.7600841","article-title":"Loss of c-Cbl RING finger function results in high-intensity TCR signaling and thymic deletion","volume":"24","author":"Thien","year":"2005","journal-title":"EMBO J"},{"issue":"2","key":"10.1016\/j.blre.2020.100652_bb0390","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S1097-2765(01)00183-6","article-title":"RING finger mutations that abolish c-Cbl-directed polyubiquitination and downregulation of the EGF receptor are insufficient for cell transformation","volume":"7","author":"Thien","year":"2001","journal-title":"Mol Cell"},{"issue":"4","key":"10.1016\/j.blre.2020.100652_bb0395","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.4049\/jimmunol.1003390","article-title":"Essential role of E3 ubiquitin ligase activity in Cbl-b-regulated T cell functions","volume":"186","author":"Paolino","year":"2011","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.blre.2020.100652_bb0400","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/intimm\/dxu105","article-title":"Regulation of T cell development by c-Cbl: essential role of Lck","volume":"27","author":"Chiang","year":"2015","journal-title":"Int Immunol"},{"issue":"9","key":"10.1016\/j.blre.2020.100652_bb0405","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/ng.641","article-title":"Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia","volume":"42","author":"Niemeyer","year":"2010","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.blre.2020.100652_bb0410","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ajhg.2010.06.015","article-title":"Heterozygous germline mutations in the CBL tumor-suppressor gene cause a Noonan syndrome-like phenotype","volume":"87","author":"Martinelli","year":"2010","journal-title":"Am J Hum Genet"},{"issue":"9","key":"10.1016\/j.blre.2020.100652_bb0415","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1182\/blood-2009-01-198416","article-title":"Mutations in CBL occur frequently in juvenile myelomonocytic leukemia","volume":"114","author":"Loh","year":"2009","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2020.100652_bb0420","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1182\/blood-2009-06-226340","article-title":"Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia","volume":"115","author":"Muramatsu","year":"2010","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2020.100652_bb0425","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1365-2141.2010.08393.x","article-title":"Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia","volume":"151","author":"Perez","year":"2010","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.blre.2020.100652_bb0430","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.leukres.2012.04.018","article-title":"Casitas B-cell lymphoma mutation in childhood T-cell acute lymphoblastic leukemia","volume":"36","author":"Saito","year":"2012","journal-title":"Leuk Res"},{"issue":"7","key":"10.1016\/j.blre.2020.100652_bb0435","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00439-015-1550-9","article-title":"Juvenile myelomonocytic leukemia due to a germline CBL Y371C mutation: 35-year follow-up of a large family","volume":"134","author":"Pathak","year":"2015","journal-title":"Hum Genet"},{"issue":"5","key":"10.1016\/j.blre.2020.100652_bb0440","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a002279","article-title":"ZAP-70: an essential kinase in T-cell signaling","volume":"2","author":"Wang","year":"2010","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"27","key":"10.1016\/j.blre.2020.100652_bb0445","doi-asserted-by":"crossref","first-page":"19459","DOI":"10.1074\/jbc.M113.475087","article-title":"CBL linker region and RING finger mutations lead to enhanced granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling via elevated levels of JAK2 and LYN","volume":"288","author":"Javadi","year":"2013","journal-title":"J Biol Chem"},{"issue":"10","key":"10.1016\/j.blre.2020.100652_bb0450","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1101\/gad.297135.117","article-title":"CBL family E3 ubiquitin ligases control JAK2 ubiquitination and stability in hematopoietic stem cells and myeloid malignancies","volume":"31","author":"Lv","year":"2017","journal-title":"Genes Dev"},{"issue":"10","key":"10.1016\/j.blre.2020.100652_bb0455","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.4049\/jimmunol.160.10.5018","article-title":"CBL-GRB2 interaction in myeloid immunoreceptor tyrosine activation motif signaling","volume":"160","author":"Park","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.blre.2020.100652_bb0460","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3389\/fped.2017.00113","article-title":"Unexpected findings in a child with atypical hemolytic uremic syndrome: an example of how genomics is changing the clinical diagnostic paradigm","volume":"5","author":"Seaby","year":"2017","journal-title":"Front Pediatr"},{"issue":"8","key":"10.1016\/j.blre.2020.100652_bb0465","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1136\/jmedgenet-2016-104432","article-title":"De novo mutations in CBL causing early-onset paediatric moyamoya angiopathy","volume":"54","author":"Guey","year":"2017","journal-title":"J Med Genet"},{"issue":"3","key":"10.1016\/j.blre.2020.100652_bb0470","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/pbc.25271","article-title":"Germline mutation of CBL is associated with moyamoya disease in a child with juvenile myelomonocytic leukemia and Noonan syndrome-like disorder","volume":"62","author":"Hyakuna","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"10.1016\/j.blre.2020.100652_bb0475","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/0092-8674(90)90151-4","article-title":"The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins","volume":"63","author":"Ballester","year":"1990","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.blre.2020.100652_bb0480","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0022-3476(78)80362-X","article-title":"Neurofibromatosis and childhood leukemia","volume":"92","author":"Bader","year":"1978","journal-title":"J Pediatr"},{"issue":"2","key":"10.1016\/j.blre.2020.100652_bb0485","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3324\/haematol.2009.010355","article-title":"Mitotic recombination and compound-heterozygous mutations are predominant NF1-inactivating mechanisms in children with juvenile myelomonocytic leukemia and neurofibromatosis type 1","volume":"95","author":"Steinemann","year":"2010","journal-title":"Haematologica"},{"issue":"39","key":"10.1016\/j.blre.2020.100652_bb0490","doi-asserted-by":"crossref","first-page":"5816","DOI":"10.1038\/sj.onc.1210361","article-title":"Genome-wide single-nucleotide polymorphism analysis in juvenile myelomonocytic leukemia identifies uniparental disomy surrounding the NF1 locus in cases associated with neurofibromatosis but not in cases with mutant RAS or PTPN11","volume":"26","author":"Flotho","year":"2007","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.blre.2020.100652_bb0495","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1182\/blood.V92.1.267.413a31_267_272","article-title":"Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1","volume":"92","author":"Side","year":"1998","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2020.100652_bb0500","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1182\/blood-2006-05-025395","article-title":"Beta common receptor inactivation attenuates myeloproliferative disease in Nf1 mutant mice","volume":"109","author":"Kim","year":"2007","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.blre.2020.100652_bb0505","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.1182\/blood-2003-08-2650","article-title":"Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder","volume":"103","author":"Le","year":"2004","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.blre.2020.100652_bb0510","doi-asserted-by":"crossref","first-page":"9427","DOI":"10.1128\/JVI.75.19.9427-9434.2001","article-title":"Retroviral integration at the Epi1 locus cooperates with Nf1 gene loss in the progression to acute myeloid leukemia","volume":"75","author":"Blaydes","year":"2001","journal-title":"J Virol"},{"issue":"7","key":"10.1016\/j.blre.2020.100652_bb0515","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/ajh.22035","article-title":"Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype","volume":"86","author":"Wiesner","year":"2011","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.blre.2020.100652_bb0520","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/pbc.20176","article-title":"Activating FLT3 mutations are rare in children with juvenile myelomonocytic leukemia","volume":"44","author":"Gratias","year":"2005","journal-title":"Pediatr Blood Cancer"},{"issue":"15","key":"10.1016\/j.blre.2020.100652_bb0525","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1182\/blood-2015-05-646216","article-title":"Timing of the loss of Pten protein determines disease severity in a mouse model of myeloid malignancy","volume":"127","author":"Liu","year":"2016","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.blre.2020.100652_bb0530","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1001\/archderm.1995.01690200040007","article-title":"Juvenile xanthogranuloma, neurofibromatosis, and juvenile chronic myelogenous leukemia. World statistical analysis","volume":"131","author":"Zvulunov","year":"1995","journal-title":"Arch Dermatol"},{"issue":"9","key":"10.1016\/j.blre.2020.100652_bb0535","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/01.mph.0000135282.39550.99","article-title":"Juvenile myelomonocytic leukemia presenting with features of hemophagocytic lymphohistiocytosis in association with neurofibromatosis and juvenile xanthogranulomas","volume":"26","author":"Shin","year":"2004","journal-title":"J Pediatr Hematol Oncol"},{"issue":"2","key":"10.1016\/j.blre.2020.100652_bb0540","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.0736-8046.2004.21201.x","article-title":"Juvenile xanthogranuloma associated with neurofibromatosis 1: 14 patients without evidence of hematologic malignancies","volume":"21","author":"Cambiaghi","year":"2004","journal-title":"Pediatr Dermatol"},{"issue":"1","key":"10.1016\/j.blre.2020.100652_bb0545","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/pbc.22297","article-title":"Juvenile xanthogranuloma in a child with previously unsuspected neurofibromatosis type 1 and juvenile myelomonocytic leukemia","volume":"54","author":"Raygada","year":"2010","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"10.1016\/j.blre.2020.100652_bb0550","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1111\/pde.12478","article-title":"Neurofibromatosis type 1 diagnosed in a child based on multiple juvenile xanthogranulomas and juvenile myelomonocytic leukemia","volume":"32","author":"Jans","year":"2015","journal-title":"Pediatr Dermatol"},{"issue":"6","key":"10.1016\/j.blre.2020.100652_bb0555","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/leu.2010.18","article-title":"ALK fusion genes in children with atypical myeloproliferative leukemia","volume":"24","author":"Rottgers","year":"2010","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.blre.2020.100652_bb0560","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1158\/0008-5472.CAN-03-4026","article-title":"HCMOGT-1 is a novel fusion partner to PDGFRB in juvenile myelomonocytic leukemia with t(5;17)(q33;p11.2)","volume":"64","author":"Morerio","year":"2004","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.blre.2020.100652_bb0565","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/sj.leu.2404596","article-title":"Fusion of FIP1L1 and RARA as a result of a novel t(4;17)(q12;q21) in a case of juvenile myelomonocytic leukemia","volume":"21","author":"Buijs","year":"2007","journal-title":"Leukemia"},{"issue":"16","key":"10.1016\/j.blre.2020.100652_bb0570","doi-asserted-by":"crossref","first-page":"4315","DOI":"10.1093\/hmg\/ddu148","article-title":"Activating mutations in RRAS underlie a phenotype within the RASopathy spectrum and contribute to leukaemogenesis","volume":"23","author":"Flex","year":"2014","journal-title":"Hum Mol Genet"},{"issue":"9","key":"10.1016\/j.blre.2020.100652_bb0575","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.3324\/haematol.2010.024984","article-title":"Mutations in the let-7 binding site \u2013 a mechanism of RAS activation in juvenile myelomonocytic leukemia?","volume":"95","author":"Steinemann","year":"2010","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.blre.2020.100652_bb0580","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1182\/blood-2015-09-667808","article-title":"LIN28B overexpression defines a novel fetal-like subgroup of juvenile myelomonocytic leukemia","volume":"127","author":"Helsmoortel","year":"2016","journal-title":"Blood"},{"issue":"34","key":"10.1016\/j.blre.2020.100652_bb0585","doi-asserted-by":"crossref","first-page":"55395","DOI":"10.18632\/oncotarget.10577","article-title":"MicroRNA fingerprints in juvenile myelomonocytic leukemia (JMML) identified miR-150-5p as a tumor suppressor and potential target for treatment","volume":"7","author":"Leoncini","year":"2016","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.blre.2020.100652_bb0590","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2018.189977","article-title":"The long non-coding RNA landscape in juvenile myelomonocytic leukemia","volume":"103","author":"Hofmans","year":"2018","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.blre.2020.100652_bb0595","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/ajmg.a.34439","article-title":"Occurrence of acute lymphoblastic leukemia and juvenile myelomonocytic leukemia in a patient with Noonan syndrome carrying the germline PTPN11 mutation p.E139D","volume":"158A","author":"Pauli","year":"2012","journal-title":"Am J Med Genet A"},{"issue":"2","key":"10.1016\/j.blre.2020.100652_bb0600","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2141.2011.08817.x","article-title":"Constitutional trisomy 8p11.21-q11.21 mosaicism: a germline alteration predisposing to myeloid leukaemia","volume":"155","author":"Ripperger","year":"2011","journal-title":"Br J Haematol"},{"issue":"18","key":"10.1016\/j.blre.2020.100652_bb0605","doi-asserted-by":"crossref","first-page":"4871","DOI":"10.1182\/blood-2010-08-298968","article-title":"Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia with poor outcome","volume":"117","author":"Olk-Batz","year":"2011","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.blre.2020.100652_bb0610","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0145394","article-title":"Aberrant DNA methylation is associated with a poor outcome in juvenile myelomonocytic leukemia","volume":"10","author":"Sakaguchi","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.blre.2020.100652_bb0615","doi-asserted-by":"crossref","DOI":"10.1186\/s13148-016-0216-3","article-title":"CREBBP is a target of epigenetic, but not genetic, modification in juvenile myelomonocytic leukemia","volume":"8","author":"Fluhr","year":"2016","journal-title":"Clin Epigenetics"},{"issue":"8","key":"10.1016\/j.blre.2020.100652_bb0620","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1080\/15592294.2017.1356959","article-title":"Epigenetic dysregulation of the erythropoietic transcription factor KLF1 and the beta-like globin locus in juvenile myelomonocytic leukemia","volume":"12","author":"Fluhr","year":"2017","journal-title":"Epigenetics"},{"issue":"6","key":"10.1016\/j.blre.2020.100652_bb0625","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/jhg.2016.8","article-title":"Adults with germline CBL mutation complicated with juvenile myelomonocytic leukemia at infancy","volume":"61","author":"Muraoka","year":"2016","journal-title":"J Hum Genet"},{"issue":"24","key":"10.1016\/j.blre.2020.100652_bb0630","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1182\/blood-2008-11-187880","article-title":"Methotrexate\/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study","volume":"113","author":"Schmiegelow","year":"2009","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2020.100652_bb0635","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27034","article-title":"Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: a Children's Oncology Group study","volume":"65","author":"Dvorak","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"10.1016\/j.blre.2020.100652_bb0640","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s12185-015-1877-y","article-title":"Serial investigation of PTPN11 mutation in nonhematopoietic tissues in a patient with juvenile myelomonocytic leukemia who was treated with unrelated cord blood transplantation","volume":"102","author":"Hiramoto","year":"2015","journal-title":"Int J Hematol"},{"issue":"1","key":"10.1016\/j.blre.2020.100652_bb0645","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1172\/JCI63193","article-title":"Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice","volume":"123","author":"Chang","year":"2013","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.blre.2020.100652_bb0650","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/leu.2016.14","article-title":"Targeting the PI3K\/Akt pathway in murine MDS\/MPN driven by hyperactive Ras","volume":"30","author":"Akutagawa","year":"2016","journal-title":"Leukemia"},{"issue":"76","key":"10.1016\/j.blre.2020.100652_bb0655","doi-asserted-by":"crossref","first-page":"76ra27","DOI":"10.1126\/scitranslmed.3001069","article-title":"A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice","volume":"3","author":"Lyubynska","year":"2011","journal-title":"Sci Transl Med"},{"issue":"18","key":"10.1016\/j.blre.2020.100652_bb0660","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1182\/blood-2013-10-535104","article-title":"PI3K p110delta uniquely promotes gain-of-function Shp2-induced GM-CSF hypersensitivity in a model of JMML","volume":"123","author":"Goodwin","year":"2014","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2020.100652_bb0665","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.3324\/haematol.2015.136002","article-title":"Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency","volume":"101","author":"Sachs","year":"2016","journal-title":"Haematologica"},{"issue":"49","key":"10.1016\/j.blre.2020.100652_bb0670","doi-asserted-by":"crossref","first-page":"84776","DOI":"10.18632\/oncotarget.21455","article-title":"Pharmacologic inhibition of PI3K p110delta in mutant Shp2E76K-expressing mice","volume":"8","author":"Deng","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.blre.2020.100652_bb0675","article-title":"Use of rapamycin in a patient with juvenile myelomonocytic leukemia: a case report","volume":"5","author":"Upadhyay","year":"2017","journal-title":"J Investig Med High Impact Case Rep"},{"issue":"6","key":"10.1016\/j.blre.2020.100652_bb0680","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1172\/JCI74182","article-title":"Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm","volume":"124","author":"Kong","year":"2014","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.blre.2020.100652_bb0685","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41375-018-0169-y","article-title":"Mutation-specific signaling profiles and kinase inhibitor sensitivities of juvenile myelomonocytic leukemia revealed by induced pluripotent stem cells","volume":"33","author":"Tasian","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2020.100652_bb0690","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-016-0256-3","article-title":"Anti-proliferative effects of T cells expressing a ligand-based chimeric antigen receptor against CD116 on CD34(+) cells of juvenile myelomonocytic leukemia","volume":"9","author":"Nakazawa","year":"2016","journal-title":"J Hematol Oncol"},{"issue":"12","key":"10.1016\/j.blre.2020.100652_bb0695","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1182\/blood-2008-12-195693","article-title":"Intriguing response to azacitidine in a patient with juvenile myelomonocytic leukemia and monosomy 7","volume":"113","author":"Furlan","year":"2009","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.blre.2020.100652_bb0700","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1182\/blood-2015-01-619734","article-title":"Bridging to transplant with azacitidine in juvenile myelomonocytic leukemia: a retrospective analysis of the EWOG-MDS study group","volume":"125","author":"Cseh","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2020.100652_bb0705","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/bjh.14876","article-title":"Whole Genome MBD-seq reveals different CpG methylation patterns in Azacytidine-treated Juvenile myelomonocytic Leukaemia (JMML) patients","volume":"182","author":"Leoncini","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2020.100652_bb0710","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.semcancer.2017.10.011","article-title":"DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia","volume":"51","author":"Flotho","year":"2018","journal-title":"Semin Cancer Biol"},{"issue":"2","key":"10.1016\/j.blre.2020.100652_bb0715","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/bjh.16060","article-title":"Essential role of PTPN11 mutation in enhanced haematopoietic differentiation potential of induced pluripotent stem cells of juvenile myelomonocytic leukaemia","volume":"187","author":"Shigemura","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2020.100652_bb0720","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.scr.2018.07.001","article-title":"Generation of a human Juvenile myelomonocytic leukemia iPSC line, CHOPi001-A, with a mutation in CBL","volume":"31","author":"Gagne","year":"2018","journal-title":"Stem Cell Res"},{"issue":"24","key":"10.1016\/j.blre.2020.100652_bb0725","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1182\/blood-2013-01-478412","article-title":"Patient-derived induced pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic leukemia","volume":"121","author":"Gandre-Babbe","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2020.100652_bb0730","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/jcmm.13977","article-title":"Immunometabolism features of metabolic deregulation and cancer","volume":"23","author":"Wang","year":"2019","journal-title":"J Cell Mol Med"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X20300023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X20300023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T13:45:44Z","timestamp":1778679944000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X20300023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":146,"alternative-id":["S0268960X20300023"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2020.100652","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"After 95\u202fyears, it's time to eRASe JMML","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2020.100652","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100652"}}